← Back to patent-cliff list
Acarbose/Orlistat
Tier C — Watch / tradeAcarbose/Orlistat
Empros Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MGAM, LIPF
Indications (approved)：Overweight, Obesity
Regional status
US
-
EU
Phase II
2020-05-07
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Acarbose/Orlistat?
Approved indications include: Overweight, Obesity.
When does the Acarbose/Orlistat patent expire?
No public expiry year is available for Acarbose/Orlistat yet; this page updates once verified.
How do I get a quote for Acarbose/Orlistat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07